WeVote
Log In

Bill

Bill

H 859

An act relating to psychedelic therapy and clinical drug development trials

2025-2026 Regular Session Introduced by Conor Casey and 5 co-sponsors

Vermont bill authorizing psychedelic-assisted therapy clinical trials to treat mental health conditions while navigating federal drug scheduling conflicts.

Read first time and referred to the Committee on Health Care
0
WeVote Research Nonpartisan
Bill Summary · H 859

Legislative bill overview

H.859 appears to be Vermont legislation that would establish a framework for psychedelic-assisted therapy and clinical drug development trials within the state. The bill likely aims to create regulatory pathways for therapeutic research involving substances like psilocybin, MDMA, or other psychedelics that show promise in treating conditions like PTSD, depression, and end-of-life anxiety. This would position Vermont among states pioneering legal therapeutic access to these compounds.

Why is this important

Psychedelic-assisted therapy has demonstrated significant clinical efficacy in peer-reviewed research for treatment-resistant conditions that conventional medications often fail to address. Establishing a state-level framework could enable qualified patients to access these therapies, create local research opportunities, and potentially generate economic activity through clinical trial infrastructure. However, this represents a departure from federal drug scheduling, creating legal and regulatory tensions.

Potential points of contention

  • Federal-state legal conflict: Psilocybin and MDMA remain Schedule I controlled substances federally, creating potential conflicts between state authorization and federal law enforcement priorities
  • Clinical safety and oversight: Questions about appropriate medical supervision standards, training requirements for therapists, and protocols to prevent misuse in non-clinical settings
  • Insurance and access equity: Whether therapies will be covered by insurance, creating potential disparities in who can afford treatment versus relying on clinical trial participation

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.